Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: Insulin glargine
INDICATION: Diabetes Mellitus
DATE: 23/06/2016
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
